Capitalizing on a gene therapy boom, Avrobio locks in $60M – MedCity News
MedCity News |
Capitalizing on a gene therapy boom, Avrobio locks in $60M
MedCity News Cambridge, Massachusetts-based Avrobio has closed an oversubscribed $60 million Series B financing round to further its ex vivo lentiviral platform for the treatment of lysosomal storage disorders. It's one more sign that after decades of ups and downs … |
